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Abstract
Background
It is now well recognised that the risk of severe COVID-19 increases with some long-term
conditions (LTCs). However, prior research primarily focuses on individual LTCs and there
is a lack of data on the influence of multimorbidity (�2 LTCs) on the risk of COVID-19. Given
the high prevalence of multimorbidity, more detailed understanding of the associations with
multimorbidity and COVID-19 would improve risk stratification and help protect those most
vulnerable to severe COVID-19. Here we examine the relationships between multimorbidity,
polypharmacy (a proxy of multimorbidity), and COVID-19; and how these differ by sociode-
mographic, lifestyle, and physiological prognostic factors.
Methods and findings
We studied data from UK Biobank (428,199 participants; aged 37–73; recruited 2006–2010)
on self-reported LTCs, medications, sociodemographic, lifestyle, and physiological mea-
sures which were linked to COVID-19 test data. Poisson regression models examined risk
of COVID-19 by multimorbidity/polypharmacy and effect modification by COVID-19 prog-
nostic factors (age/sex/ethnicity/socioeconomic status/smoking/physical activity/BMI/sys-
tolic blood pressure/renal function). 4,498 (1.05%) participants were tested; 1,324 (0.31%)
tested positive for COVID-19. Compared with no LTCs, relative risk (RR) of COVID-19 in
those with 1 LTC was no higher (RR 1.12 (CI 0.96–1.30)), whereas those with�2 LTCs had
48% higher risk; RR 1.48 (1.28–1.71). Compared with no cardiometabolic LTCs, having 1
and�2 cardiometabolic LTCs had a higher risk of COVID-19; RR 1.28 (1.12–1.46) and 1.77
(1.46–2.15), respectively. Polypharmacy was associated with a dose response higher risk
of COVID-19. All prognostic factors were associated with a higher risk of COVID-19 infection
in multimorbidity; being non-white, most socioeconomically deprived, BMI�40 kg/m2, and
reduced renal function were associated with the highest risk of COVID-19 infection: RR 2.81
(2.09–3.78); 2.79 (2.00–3.90); 2.66 (1.88–3.76); 2.13 (1.46–3.12), respectively. No
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multiplicative interaction between multimorbidity and prognostic factors was identified.
Important limitations include the low proportion of UK Biobank participants with COVID-19
test data (1.05%) and UK Biobank participants being more affluent, healthier and less ethni-
cally diverse than the general population.
Conclusions
Increasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are
associated with a higher risk of developing COVID-19. Those with multimorbidity and addi-
tional factors, such as non-white ethnicity, are at heightened risk of COVID-19.
Introduction
COVID-19 is an ongoing pandemic caused by the severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) [1–3]. COVID-19 clinical manifestations range from asymptomatic and
mild upper respiratory symptoms to severe respiratory failure and death [4]. A range of prog-
nostic factors for greater mortality from COVID-19 have been identified including age [5],
male sex [6], non-white ethnicity [7], obesity [8], pre-existing long-term conditions (LTCs; e.g.
hypertension [9], diabetes [10], chronic kidney disease [11]), and multimorbidity (presence of
�2 LTCs) [11–13]. As a result, a key mitigation strategy in many countries is the identification
and protection of those deemed vulnerable or at higher risk of adverse outcomes [14].
For example, in both the UK and the USA, age (�70 in UK and�65 in USA), severe obesity
(BMI�40 kg/m2), being immunocompromised, and certain LTCs (e.g. cardiac/respiratory/
renal disease) are used to identify those at higher risk of severe disease [14, 15]. Individuals
who meet any of these criteria have been asked to be more cautious and adhere to public health
guidance (e.g. social distancing) more strictly than the general population. In the UK, this
higher-risk group is distinct from those with specific LTCs (e.g. leukaemia) who are consid-
ered ‘extremely high risk’ and, as a result, are asked to ‘shield’ and not leave their homes at all
[16].
To date, LTC prognostic factors for severe COVID-19 primarily involve single conditions
and there is a lack of data on the influence of multimorbidity on the risk of COVID-19 [5, 13,
17]. Multimorbidity prevalence is increasing worldwide and is associated with higher mortal-
ity, with different disease clusters associated with even higher mortality [18–21]. Polyphar-
macy, closely linked to multimorbidity [22], is also associated with adverse health outcomes
[23]. Therefore, it is plausible that the number of LTCs, type of LTCs, and polypharmacy are
associated with a higher risk of developing severe COVID-19. Furthermore, it is plausible that
the adverse consequences of multimorbidity on COVID-19 risk may be greater for population
subgroups (e.g. people aged�65 years, or those with a BMI�40kg/m2). Such knowledge
would benefit clinicians, as this is routinely collected information in many clinical settings.
Using a large UK population cohort, UK Biobank, we aimed to investigate:
1. the association between multimorbidity (by number and type of LTC, and by level of poly-
pharmacy) and COVID-19.
2. the potential effect modification of known COVID-19 sociodemographic and physiological
risk factors on the association between multimorbidity and COVID-19.
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Methods
Study design and data collection
Data came from UK Biobank, a longitudinal population-based cohort of 502,503 participants
aged between 37–73 years old at baseline from England, Wales and Scotland [24]. Baseline
data were collected across 22 assessment centres between 2006–2010. UK Biobank contains
detailed biological measurements and self-reported demographic, lifestyle, and health infor-
mation elicited by touch-screen questionnaire and nurse-led interview. COVID-19 test sam-
ples were collected and processed between 16 March 2020 and 18th May 2020. COVID-19 test
results were provided by Public Health England (PHE) [25]. Data presented here are from par-
ticipants recruited from 16 assessment centres located in England only (5 participants with
COVID-19 test data were excluded as they attended baseline assessment centres in Scotland or
Wales). Participants who had died prior to the last available mortality register extraction (14
February 2018) were also excluded. This resulted in a final eligible study population of 428,199
participants.
This study was conducted as part of UK Biobank project number 14151 and is covered by
the generic ethics approval for UK Biobank studies from the NHS National Research Ethics
Service (16/NW/0274).
Outcomes
Our outcome of interest was confirmed COVID-19 infection (defined as at least one positive
test result). Whether or not participants received a COVID-19 test was used as an outcome for
a secondary analysis, presented in Supplementary Material (S1–S3 Tables).
Measurement of LTCs
Physician-diagnosed LTCs were self-reported and confirmed at nurse-led interview at base-
line. Number of LTCs, based on 43 commonly occurring LTCs from previous UK Biobank
work [21], were categorised into 0, 1, and�2. When used as a predictor variable for COVID-
19, LTCs were modelled using three measures: total number of LTCs; number of cardiometa-
bolic LTCs (diabetes, coronary heart disease, atrial fibrillation, chronic heart failure, chronic
kidney disease, hypertension, stroke/transient ischaemic attack, or peripheral vascular disease);
and number of respiratory LTCs (asthma, chronic obstructive pulmonary disease, chronic
bronchitis, emphysema, or bronchiectasis).
Measurement of polypharmacy
Participant medication numbers were based on self-report at baseline and categorised into: 0,
1–3, 4–6, 7–9 and,�10 medications.
Exposures
As for LTC and polypharmacy measures, all exposures were based on assessment at the time of
recruitment. Sex was collected as a binary variable (male/female). Age at time of COVID-19
test was calculated using age at baseline, and dates of baseline assessment and COVID-19 test
extract, and categorised as 48–59, 60–69, and 70–86 years. Ethnicity was self-reported and cat-
egorised as Asian/Asian British, black/black British, Chinese, mixed, white and other. Socio-
economic deprivation was measured using the Townsend score of participants’ postcode of
residence derived from Census data on car ownership, household occupancy, unemployment,
and occupation and categorised into quintiles [26]. Smoking status was dichotomised as never
and current/former. Frequency of alcohol intake was categorised into: “Never or special
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occasions only”, “1–3 times a month”, “1–4 times a week”, or “Daily or almost daily”. Level of
physical activity was defined as “none”, “low”, “medium”, or “high” using Metabolic Equiva-
lent Task (MET) scores based on the International Physical Activity Questionnaire (IPAQ)
scoring protocol [27]. Assessment centre location, a categorical variable, describes attendance
at one of sixteen assessment centres included in this study. BMI was derived from weight and
height and categorised as<18.5, 18.5–25, 25–30, 30–35, or >35 kg/m2. The UK Biobank study
protocol is described in more detailed online [28].
To assess potential effect modification on the association between multimorbidity and
COVID-19, known COVID-19 risk factors were re-categorised into dichotomous variables
based on at-risk status: age (</�65 years), ethnicity (white/non-white), physical activity (</�
current UK guidelines of 150 min/week moderate or 75 min/week vigorous physical activity)
[29], and BMI (</�40kg/m2; severely obese) [15]. Due to previously identified associations
with severe COVID-19, two additional physiological risk factors were also included in this
analysis: raised systolic blood pressure (</�140 mmHg) as a marker of hypertension [9]; and
reduced estimated glomerular filtration rate (eGFR; </�60 ml/min/1.73 m2), with<60 ml/
min/1.73 m2 used as a marker of chronic kidney disease [30]. eGFR was calculated by the
CKD-EPI equation [31].
Statistical analyses
We compared participants who tested positive for COVID-19 with those who tested nega-
tive or were not tested, based on sociodemographics (age, sex, Townsend score and ethnic-
ity), lifestyle (smoking status, frequency of alcohol intake, physical activity), BMI, LTCs,
and medication counts using χ2 tests. Poisson regression models were then used to test for
an association between outcome measure (confirmed COVID-19 infection vs. no COVID-
19 infection, including those with a negative result and those not tested) and number of
LTCs (all, cardiometabolic and respiratory LTCs)/level of polypharmacy. We chose Poisson
regression models rather than logistic regression to provide more interpretable relative
risks as opposed to odds ratios [32]. Participants with no LTCs, no cardiometabolic LTCs,
no respiratory LTCs, or not taking any medication formed the respective reference groups.
Two models were conducted, adjusting for 1) sociodemographic variables (as above plus
assessment centre location), and 2) as for model 1 adjustments plus lifestyle variables and
BMI. For both χ2 tests and Poisson regression models, p<0.01 was considered statistically
significant.
Next, we assessed whether there was evidence of effect modification on an additive scale by
examining how the association between multimorbidity and COVID-19 differed across strata
of known COVID-19 risk factors: sex, age, ethnicity, Townsend score, smoking, physical activ-
ity, BMI, systolic blood pressure, and eGFR. For each risk factor, the reference category was
participants in the lowest risk category for that risk factor who also had no LTCs. We used
Poisson regression models to examine the association between LTC and COVID-19 across the
other combinations of LTC and risk factor categories. We tested formally for interactions by
performing ANOVA tests between two models for each risk factor: one model containing an
interaction term between the risk factor and number of LTCs, and one without the interaction
term. Interactions were considered significant if p<0.01 for each ANOVA. As a secondary
analysis we re-ran the analyses with the outcome as tested vs. not tested for COVID-19. The
number of participants in each model varied depending on the proportion missing data for
any included variable, however, the maximum proportion of missing data for any variable of
interest was 2.9% (N = 12,350) for systolic blood pressure. All analyses were conducted using
R studio v.1.2.1335 operating R v.3.6.1.
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Results
Demographic and lifestyle factors
Of 428,199 eligible participants, 1,324 (0.31%) tested positive for COVID-19. Participants who
tested positive for COVID-19 were older and more likely to be male, non-white, in the most
deprived quintile, current/former smokers, drink alcohol rarely, to have a BMI of�40 kg/m2,
do no physical activity, to have more LTCs (including cardiometabolic and respiratory LTCs),
and to be taking more medications, compared to those who did not have a positive COVID-19
test (Table 1).
Table 1. Cohort characteristics by COVID-19 test positive or not.
COVID-19 test negative or not tested COVID-19 test positive
(n = 426,875) (n = 1,324)
Sex
Female 234,507 628
54.9 % 47.4 %
Male 192,368 696
45.1 % 52.6 %
Age at COVID-19 test (years)
48–59 94,652 381
22.2 % 28.8 %
60–69 139,817 307
32.8 % 23.2 %
70–86 192,406 636
45.1 % 48.0 %
Ethnicity
White 399,388 1,139
94.1 % 86.7 %
Asian or Asian British 9,186 60
2.2 % 4.6 %
Black or Black British 7,650 76
1.8 % 5.8 %
Chinese 1,396 6
0.3 % 0.5 %
Mixed 2,652 9
0.6 % 0.7 %
Other ethnic group 4,181 23
1.0 % 1.8 %
Townsend quintile
1 (least deprived) 84,840 179
19.9 % 13.5 %
2 86,510 207
20.3 % 15.6 %
3 85,788 222
20.1 % 16.8 %
4 85,402 290
20.0 % 21.9 %
5 (most deprived) 83,835 425
19.7 % 32.1 %
(Continued)
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Table 1. (Continued)
COVID-19 test negative or not tested COVID-19 test positive
(n = 426,875) (n = 1,324)
Smoking status
Never 235,056 642
55.4 % 49 %
Current or Previous 189,299 669
44.6 % 51.0 %
Frequency of alcohol intake
Never or special occasions only 82,785 363
19.5 % 27.5 %
One to three times a month 47,535 183
11.2 % 13.9 %
One to four times a week 208,046 563
48.9 % 42.7 %
Daily or almost daily 87,211 209
20.5 % 15.9 %
Physical activity level
None 25,887 157
6.2 % 12.2 %
Low 15,687 51
3.7 % 4.0 %
Medium 335,775 957
79.8 % 74.5 %
High 43,383 120
10.3 % 9.3 %
BMI (kg/m2)
<18.5 2,138 7
0.5 % 0.5 %
18.5–25 135,563 297
31.9 % 22.7 %
25–30 182,243 551
42.9 % 42.1 %
30–35 75,201 282
17.7 % 21.5 %
�35 29,210 172
6.9 % 13.1 %
Number of long-term conditions
0 148,826 351
35.0 % 26.8 %
1 139,963 385
32.9 % 29.4 %
� 2 136,508 572
32.1 % 43.7 %
Number of cardiometabolic long-term conditions
0 300,363 773
70.4 % 58.4 %
1 103,185 394
24.2 % 29.8 %
(Continued)
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Multimorbidity and COVID-19
In the fully adjusted model (Model 2), compared to those with no LTCs, participants with 1
LTC had no higher risk of having a positive test for COVID-19 (RR 1.12 (0.96–1.30) p = 0.15),
but those with�2 LTCs had a 48% higher risk (RR 1.48 (1.28–1.71) p<0.01) (Table 2). Com-
pared to those with no cardiometabolic LTCs, those with 1 cardiometabolic LTC had a 28%
higher risk (RR 1.28 (1.12–1.46) p<0.01), and those with�2 cardiometabolic LTCs had a 77%
higher risk (RR 1.77 (1.46–2.15) p<0.01) (Table 2). Participants with one respiratory LTC had
no greater risk of a positive COVID-19 test compared to those with no respiratory LTCs (RR
1.14 (0.97–1.33) p = 0.12; Table 2). There was a higher risk of having a positive COVID-19 test
in those with�2 respiratory LTCs (RR 1.78 (1.10–2.88) p = 0.02) compared to 0 respiratory
LTCs but this did not meet our p-value threshold of 0.01. However, it is a similar higher risk
observed (78%) as for participants with�2 cardiometabolic conditions (77%); the lack of sta-
tistical significance may be explained by the much lower number of participants in the group
with�2 respiratory LTCs (N = 2,641) compared to�2 cardiometabolic conditions
(N = 23,484).
Polypharmacy and COVID-19
Compared to those taking no medications, in the fully adjusted model (Model 2) there was a
clear dose relationship whereby the risk of a COVID-19 positive test rose steadily with poly-
pharmacy level (Table 2): 4–6 medications (RR 1.41 (1.18–1.67) p<0.01); 7–9 medications (RR
1.86 (1.49–2.33) p<0.01); and�10 medications (RR 2.42 (1.82–3.21) p<0.01).
Table 1. (Continued)
COVID-19 test negative or not tested COVID-19 test positive
(n = 426,875) (n = 1,324)
� 2 23,327 157
5.5 % 11.9 %
Number of respiratory long-term conditions
0 373,026 1,120
87.4 % 84.6 %
1 51,226 186
12.0 % 14.0 %
� 2 2,623 18
0.6 % 1.4 %
Number of medications
0 121,288 296
28.5 % 22.4 %
1–3 197,296 526
46.3 % 39.8 %
4–6 76,265 298
17.9 % 22.5 %
7–9 22,779 130
5.3 % 9.8 %
� 10 8,538 72
2 % 5.4 %
This table uses participants with COVID-19 positive tests as positive group and all other participants as negative
group. All chi squared tests p<0.01.
https://doi.org/10.1371/journal.pone.0238091.t001
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Interactions between COVID-19 prognostic factors and multimorbidity
For all risk factors examined, there was a general trend of higher risk of a positive COVID-
19 test with increasing LTCs and at-risk subgroups (Fig 1; Table 3). Further, for all prognos-
tic factors, in participants with �2 LTCs there was a higher risk of a positive COVID-19 test
for each risk factor subgroup when examining ethnicity, physical activity, BMI, systolic
blood pressure, and eGFR. For some factors, having �2 LTCs was associated with an
increased risk of COVID-19 infection only in the at-risk sub-group: males when examining
sex; >65 years when examining age; and current/previous smoker when examining smok-
ing status. When observing the effect of socioeconomic status, significantly higher risk of
COVID-19 infection was apparent in the more deprived quintiles. There was no evidence of
a multiplicative interaction between all risk factors modelled and number of LTCs. How-
ever, there appeared to be an additive effect whereby the combination of multimorbidity
and each prognostic factor was associated with greater risk of COVID-19 infection. Of
those with no LTCs, being �65 years old was associated with 34% lower risk of COVID-19
compared with those <65 years old.
Similar results overall were observed in the secondary analysis, where the above analyses
were repeated in those who were tested for COVID-19 versus those who were not (S1–S3
Tables).
Table 2. Relative risk of positive COVID-19 test by LTC groups (Poisson regression).
Measure of Multimorbidity (n) Model 1 RR (95% CI) P value Model 2 RR (95% CI) P value
Total number of LTCs
0 (149,177) 1 (ref) - 1 (ref) -
1 (140,348) 1.18 (1.02–1.36) 0.03 1.12 (0.96–1.30) 0.15
�2 (137,080) 1.73 (1.51–1.99) ��� 1.48 (1.28–1.71) ���
Number of cardiometabolic LTCs
0 (301,136) 1 (ref) - 1 (ref) -
1 (103,579) 1.41 (1.24–1.60) ��� 1.28 (1.12–1.46) ���
�2 (23,484) 2.17 (1.82–2.60) ��� 1.77 (1.46–2.15) ���
Number of respiratory LTCs
0 (374,146) 1 (ref) - 1 (ref) -
1 (51,412) 1.20 (1.03–1.41) 0.02 1.14 (0.97–1.33) 0.12
�2 (2,641) 2.09 (1.31–3.33) ��� 1.78 (1.10–2.88) 0.02
Number of medications
0 (121,584) 1 (ref) - 1 (ref) -
1–3 (192,822) 1.13 (0.98–1.31) 0.10 1.07 (0.93–1.24) 0.36
4–6 (76,563) 1.58 (1.34–1.87) ��� 1.41 (1.18–1.67) ���
7–9 (22,909) 2.24 (1.81–2.77) ��� 1.86 (1.49–2.33) ���
� 10 (8,610) 3.09 (2.37–4.03) ��� 2.42 (1.82–3.21) ���
Model 1: Adjusted for age, sex, Townsend score, ethnicity, and assessment centre location. Model 2: As model 1 and additionally adjusted for smoking status, alcohol
intake frequency, BMI, and physical activity. RR = Relative risk; CI = confidence interval; n = number of participants; LTC = long-term condition; Cardiometabolic
LTC = diabetes, coronary heart disease, atrial fibrillation, chronic heart failure, chronic kidney disease, hypertension, stroke/TIA or peripheral vascular disease;
Respiratory LTC = asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, or bronchiectasis.
���p<0.01 Note: These results show the RR of a positive COVID-19 test versus a negative COVID-19 test or not tested (counterfactual group contains both participants
who have a negative COVID-19 test result and participants who were not tested (n = 426,875)).
https://doi.org/10.1371/journal.pone.0238091.t002
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Fig 1. Relative risk of positive COVID-19 test by long-term condition count and prognostic factors (Poisson
regression). Prognostic factors: a) Sex, b) Age (years), c) Ethnicity, d) Townsend quintile (1 least deprived; 5 most
deprived), e) Smoking status, f) Physical activity level (based on UK guidelines), g) Body-mass index (BMI; kg/m2), h)
Systolic blood pressure (mmHg), and i) estimated glomerular filtration rate (eGFR; ml/min/1.73m2). Models were
adjusted for sex, age, ethnicity, Townsend score, smoking status, alcohol intake frequency, physical activity, BMI, and
assessment centre location.
https://doi.org/10.1371/journal.pone.0238091.g001
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Table 3. Relative risk of positive COVID-19 test by LTC count and prognostic factors (Poisson regression).
Prognostic factor LTC count Prognostic factor subgroup N Relative risk (95% CI) P value
Sex 0 Female 80,212 1 (ref)
Male 68,965 1.08 (0.87–1.33) 0.51
1 Female 76,383 0.95 (0.77–1.18) 0.67
Male 63,965 1.39 (1.13–1.71) ���
�2 Female 77,492 1.24 (1.01–1.51) 0.04
Male 59,588 1.88 (1.54–2.29) ���
Age at COVID-19 test (years) 0 < 65 16,470 1 (ref)
� 65 132,707 0.66 (0.53–0.82) ���
1 < 65 25,029 1.07 (0.87–1.31) 0.51
� 65 115,319 0.82 (0.68–1.00) 0.05
�2 < 65 36,865 0.99 (0.79–1.25) 0.96
� 65 100,215 1.29 (1.09–1.53) ���
Ethnicity 0 White 138,677 1 (ref)
Other 9,492 1.84 (1.34–2.54) ���
1 White 131,644 1.10 (0.94–1.29) 0.24
Other 8,055 2.28 (1.67–3.11) ���
�2 White 129,033 1.47 (1.26–1.72) ���
Other 7,408 2.81 (2.09–3.78) ���
Townsend quintile (1-least deprived; 5-most deprived) 0 1 30,995 1 (ref)
2 31,206 1.24 (0.84–1.82) 0.28
3 30,394 1.19 (0.80–1.75) 0.39
4 29,633 1.46 (1.01–2.12) 0.04
5 26,956 1.96 (1.37–2.80) ���
1 1 28,723 1.47 (1.00–2.14) 0.05
2 28,898 1.34 (0.92–1.97) 0.13
3 28,605 1.39 (0.95–2.04) 0.09
4 27,950 1.79 (1.25–2.46) ���
5 26,005 1.79 (1.19–2.70) ���
�2 1 25,310 1.57 (1.07–2.30) 0.02
2 26,585 1.75 (1.21–2.52) ���
3 26,771 1.77 (1.23–2.55) ���
4 27,764 2.22 (1.57–3.15) ���
5 20,670 2.79 (2.00–3.90) ���
Smoking status 0 never 88,737 1 (ref)
current/previous 59,500 1.26 (1.02–1.57) 0.03
1 never 77,915 1.18 (0.96–1.44) 0.11
current/previous 61,781 1.33 (1.08–1.65) 0.01
�2 never 68,324 1.39 (1.14–1.70) ���
current/previous 67,956 1.97 (1.62–2.38) ���
Physical activity level 0 � guidelines 80,715 1 (ref)
< guidelines 36,507 1.44 (1.09–1.91) 0.01
1 � guidelines 74,324 1.32 (0.94–1.83) 0.11
< guidelines 32,998 1.51 (1.13–2.00) ���
�2 � guidelines 68,226 1.87 (1.40–2.67) ���
< guidelines 29,622 1.95 (1.43–2.67) ���
(Continued)
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Discussion
Summary of key findings
This study showed that participants with multimorbidity (�2 LTCs) had a 48% higher risk of a
positive COVID-19 test, those with cardiometabolic multimorbidity had a 77% higher risk,
and those with respiratory multimorbidity a 78% higher risk (albeit not statistically significant,
p = 0.02), compared to those without that type of multimorbidity. Importantly, those from
non-white ethnicities with multimorbidity had nearly three times the risk of having COVID-
19 infection compared to those of white ethnicity, suggesting that those from minority ethnic
groups with multimorbidity are at particular risk. COVID-19 prognostic factors appeared to
have an additive effect by further increasing the risk of a positive COVID-19 test in those with
multimorbidity.
Comparison with previous literature
Previous literature has suggested that the presence of single LTCs such as hypertension, diabe-
tes, or COPD increase the risk of COVID-19 [33]. In an English primary care research cohort
of 3,802 patients, confirmed COVID-19 infections were associated with male sex, black ethnic-
ity, deprivation, chronic kidney disease, and urban setting [30]. A preprint report of linked pri-
mary care data on 17,425,445 adults in England, showed that older age, male sex, deprivation,
and black and Asian ethnicity were associated with higher risk of COVID-19 related in-hospi-
tal deaths [11]. However, our study is the first to show a higher risk of a positive COVID-19
test in those with�2 LTCs and particularly in those with cardiometabolic multimorbidity.
Table 3. (Continued)
Prognostic factor LTC count Prognostic factor subgroup N Relative risk (95% CI) P value
BMI (kg/m2) 0 <40 146,986 1 (ref)
�40 1,094 1.30 (0.49–3.50) 0.60
1 <40 137,865 1.14 (0.99–1.33) 0.08
�40 1,912 1.34 (0.63–2.85) 0.44
�2 <40 131,416 1.54 (1.33–1.78) ���
�40 4,865 2.66 (1.88–3.76) ���
Systolic blood pressure (mm Hg) 0 <140 97,526 1 (ref)
�140 47,162 0.88 (0.69–1.11) 0.28
1 <140 78,786 1.10 (0.91–1.32) 0.33
�140 57,921 1.04 (0.84–1.29) 0.73
�2 <140 68,956 1.40 (1.16–1.69) ���
�140 63,979 1.46 (1.32–1.78) ���
eGFR (ml/min/1.73m2) 0 � 60 137,083 1 (ref)
< 60 1,270 0.74 (0.18–2.96) 0.67
1 � 60 128,860 1.09 (0.93–1.28) 0.26
< 60 2,108 2.14 (1.17–3.92) 0.01
�2 � 60 123,182 1.43 (1.22–1.67) ���
< 60 4,981 2.13 (1.46–3.12) ���
Models were adjusted for sex, age, ethnicity, Townsend score, smoking status, alcohol intake frequency, physical activity, BMI, and assessment centre location.
LTC = long-term condition; BMI = body mass index; eGFR = estimated glomerular filtration rate; guidelines = UK guidelines of 150 min/week moderate or 75 min/
week vigorous physical activity.
���p<0.01.
https://doi.org/10.1371/journal.pone.0238091.t003
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It has also been suggested that the presence of multimorbidity could further increase the risk
of adverse outcomes for people with COVID-19 [33]. Guan et al, in a cohort of 1,590 hospital
patients with confirmed COVID-19, found a higher risk of a composite COVID-19 outcome
(intensive care admission, invasive ventilation, or death) in those with 1 (HR 1.79 (95%CI 1.16–
2.77)) and 2 (HR 2.59 (95%CI 1.61–4.17) comorbidities [9]. However, while they provided details
of specific LTCs most likely to be present, especially in severe cases of infection (hypertension,
cardiovascular/cerebrovascular diseases, diabetes, hepatitis B infections, COPD, chronic kidney
diseases and malignancy), they did not describe which patterns of multimorbidity were associated
with the greatest risk. A report on 3,200 patients with COVID-19 from Italy showed that, of the
481 patients who died, 48.6% had 3 or more comorbidities. However, again, while it listed the spe-
cific LTCs associated with increased risk, such as ischaemic heart disease and diabetes, it did not
describe which patterns of multimorbidity were associated with the highest risk [13].
Strengths and limitations
As a large prospective cohort with rich demographic, lifestyle, health, and anthropometric data
linked to COVID-19 test results, UK Biobank provides a valuable opportunity to examine the
predictors for COVID-19 [34, 35]. In particular, the rich data allowed examination of the risk
of a positive COVID-19 test in those with multimorbidity and the influence of a range of
known sociodemographic, lifestyle and physiological risk factors for COVID-19. However,
our study has a number of limitations. Firstly, the proportion of UK Biobank participants with
COVID-19 test data is currently low (1.05%) which resulted in wide confidence intervals for
groups with few participants. Secondly, the denominator for the test group included all those
who had a negative test result as well as those who were not tested at all. At the time for which
COVID-19 test data are available, the strategy in the UK had been to only test those in hospital
(emergency department and inpatient) settings. This means the positive COVID-19 partici-
pants are likely to have had sufficiently severe clinical signs and symptoms to justify hospital
assessment and those with COVID-19 but with mild symptoms are less likely to have been
tested. Our results are therefore likely to reflect the associations with more severe COVID-19
disease. It is not known if the associations identified in this study would be similar for those
with milder COVID-19 disease. Thirdly, exposures and moderators examined here were
assessed at baseline only and may have changed during follow up. Depending on the direction
and level of change since recruitment, more up-to-date data on exposures (e.g. smoking, alco-
hol intake, physical activity, and post code of residence) could have provided different results.
However, LTC and medication count are likely to have remained the same or increased with
time and therefore our effect size estimates may be conservative. Fourthly, UK Biobank partici-
pants are not representative of the general population and are acknowledged to be mostly
white British, more affluent, and healthier than the general population [36]. Consequently,
absolute values may not be generalisable, however, effect size estimates will be and strongly
agree with more representative cohorts [37]. Finally, participants in this study were aged
between 48–86 years old and associations between multimorbidity and COVID-19 may be dif-
ferent for younger age groups. This may be particularly important for participants from more
deprived backgrounds who are more likely to have multimorbidity at a younger age [38, 39].
Implications
Our work has clinical and practical implications as more countries navigate lifting COVID-19
restrictions. It demonstrates that multimorbidity, particularly cardiometabolic multimorbidity
and polypharmacy, are strongly associated with COVID-19 infection and suggests that those
who have multimorbidity coupled with additional risk factors, such as non-white ethnicity, are
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at increased risk. Such individuals should be particularly stringent in adhering to preventive
measures, such as physical distancing and hand hygiene. Our findings also have implications
for clinicians, occupational health and employers when considering work-place environments,
appropriate advice for patients, and adaptations that might be required to protect such staff.
Future research is needed to corroborate these findings in other countries and in people
from different ethnic backgrounds. We know that patterns of multimorbidity differ across eth-
nic groups and have different associations with mortality, so this merits further investigation
[40]. We also need to explore the implications of different patterns of multimorbidity on
COVID-19 related health care outcomes in the short and long term.
Conclusion
This study suggests that multimorbidity, cardiometabolic disease, and polypharmacy are asso-
ciated with COVID-19. Those with multimorbidity who were also of non-white ethnicity,
from the most socioeconomically deprived backgrounds, those who were severely obese, or
who had reduced renal function, had more than twice the risk of COVID-19 infection.
More work is required to develop risk stratification for COVID-19 in people with different
patterns of multimorbidity in order to better define those individuals who would benefit from
enhanced preventive measures in public, work, and residential spaces.
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